EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions. The company's developmental portfolio also encompassed several other biosimilar candidates: BOW050, a biosimilar version of Humira (adalimumab), targeting inflammatory diseases such as rheumatoid arthritis, various adult and pediatric forms of arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis. BOW070, mimicking Actemra (tocilizumab), aimed at rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. BOW080, a biosimilar to Soliris, designed to address ultra-rare blood disorders like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. BOW100, a biosimilar of SIMPONI, for inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. EPIRUS had established strategic alliances, including a licensing arrangement with Sun Pharmaceutical Industries Ltd., a joint licensing and collaboration pact with Livzon Mabpharm Inc., and a collaborative venture with Polpharma S.A. Founded in 2011, the firm maintained its corporate base in Boston, Massachusetts. However, on July 25, 2016, Epirus Biopharmaceuticals, Inc. initiated Chapter 7 liquidation proceedings by submitting a voluntary petition with the US Bankruptcy Court for the District of Massachusetts.